Diamyd Medical AB

Diamyd Medical AB
About Us
Contacts
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®.

Contacts

Ulf Hannelius

CEO

Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
+46 8 661 63 68
https://www.diamyd.com
press@diamyd.com

Quotes

The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.

Ulf Hannelius, CEO

Our top strategic priority is to prepare for a marketing application for Diamyd®

Ulf Hannelius, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Quarterly Report 1 24/25

Wed, Jan 29, 2025 08:15 CET

September 2024 – November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025Precision Medicine for Autoimmune DiabetesAiming for Accelerated Market Approval Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2024 - November 30, 2024 · Net result: MSEK -36.2 (-32.8). · Result per share: SEK -0.4 (-0.4) · Cash flow from operating activities: MSEK -41.8 (-27.8) · Cash and short-term investments at November 30, 2024: MSEK 152.9 (176.7). Events during

There are no items matching the current filter

There are no more items matching the current filter

About Us

Contacts

Links

Quotes

Quarterly Report 1 24/25

Subscribe

Media

Share

About Us

Contacts

Links

Quotes

Quarterly Report 1 24/25

Subscribe

Media